Menthol, Inflammation, and Nicotine Transition Study
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-85
SponsorRosalind Franklin University of Medicine and Science
About this trial
This study will focus on examining the potential impact of menthol flavoring in cigarettes on biomarkers of systemic inflammation as a subclinical indicator of cardiovascular disease risk.
Eligibility criteria
Qualifiers
Men and women between 21-85 years old
Currently uses menthol cigarettes
Daily smoking rate of ≥5 cigarettes/day for ≥1 year
Currently own and regularly use an iOS/Android smartphone device able to download the LifeData application
Disqualifiers
Currently pregnant or breastfeeding
Actively trying to quit smoking
Current heavy alcohol use
Frequent use of non-menthol cigarettes, other smoking products, or illicit substances
Trial design
Treatments tested in this trial
- Cigarette Type Switching
Treatment groups
68 Participants
are divided into 1 treatment groupSponsors and collaborators
Rosalind Franklin University of Medicine and Science
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov